Antisense Therapeutics (ASX:ANP) has announced that following the recent completion of the monitoring phase of the ATL1102 Phase 2 Duchenne Muscular Dystrophy (DMD) trial, the locking of the clinical trial database for final analysis is on track for the end of March 2020.
The company said it expects study results to be reported in April. It has been conducting an open-label six-month dosing trial of ATL1102 in nine non-ambulant patients with DMD at the neuromuscular centre of the Royal Children's Hospital in Melbourne.
It reported positive clinical trial results in December 2019, following completion of dosing in all participants, saying it affirmed the drug’s safety profile and positive effects on disease progression endpoints.
Antisense added it expects to report on new trial data relating to the efficacy of ATL1102 on additional disease progression endpoints once final data analysis is completed in the coming weeks.